Literature DB >> 9197348

Cholestatic effects of cyclosporine in the rat.

F K Chan1, E A Shaffer.   

Abstract

BACKGROUND: Previous studies of cyclosporine-induced cholestasis were flawed by confounders encountered in human studies and discrepancies in acute animal experiments. Even the cyclosporine vehicle, polyoxyethylated castor oil (Cremophor EL), had been implicated in cholestasis. The purpose of this study was to investigate how cyclosporine affects bile salt kinetics and biliary lipid secretion in a rat model under steady state conditions.
METHODS: Three groups of male Lewis rats (n=10) were given daily subcutaneous injections of either cyclosporine (CsA; 10 mg/kg body weight), Cremophor, or NaCl (control) for 1 week. Twenty-four-hour bile collection was performed 18 hr after the last injection. The first hour's output measured bile flow and organic bile solute secretion rates. Bile salt pool size and basal synthesis were determined with the washout technique.
RESULTS: CsA significantly reduced basal bile flow and bile salt secretion by 25%. Bile salt synthesis was suppressed 45% (CsA: 3.50+/-0.8 micromol/g liver/24 hr vs. control: 6.31+/-1.17 micromol/g liver/24 hr; P<0.05), which resulted in a 28% reduction in the bile salt pool size (CsA: 16.9+/-1.9 micromol/g liver vs. control: 23.6+/-2.0 micromol/g liver; P<0.05). Bile salt-independent flow was significantly suppressed (29%), whereas bile salt-dependent flow was only modestly reduced. Biliary phospholipid output decreased 23% (CsA: 11.7+/-0.8 nmol/min/g liver vs. control 15.2+/-1.1 nmol/min/g liver; P<0.05), but cholesterol secretion was unaltered, resulting in a 29% increase in the cholesterol saturation index (CsA: 0.40+/-0.03 vs. control 0.31+/-0.02; P<0.05). Cremophor had no significant effects on bile secretion or bile salt kinetics.
CONCLUSIONS: CsA induces cholestasis by decreasing both bile flow and bile salt secretion. Its suppression of bile salt synthesis reduces the bile salt pool size. The drug inhibits bile salt and phospholipid secretion without a corresponding change in cholesterol secretion and thus elevates cholesterol saturation in bile, a potential risk for gallstone formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9197348     DOI: 10.1097/00007890-199706150-00006

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

Review 1.  Role of formulation vehicles in taxane pharmacology.

Authors:  L van Zuylen; J Verweij; A Sparreboom
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Effect of dietary lipid (soybean lecithin and triacylglycerol) on hepatic F-actin microfilaments in cyclosporine A-treated rats: image analysis by confocal laser scanning microscopy.

Authors:  L Benkoel; F Chanussot; F Dodero; C De la Maisonneuve; P Bongrand; A M Benoliel; R Lambert; J Brisse; A Chamlian
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Effect of dietary lipids on hepatic Na+,K(+)-ATPase in cyclosporine A-treated rats: immunocytochemical analysis of alpha1 subunit by confocal laser scanning microscopy imaging.

Authors:  L Benkoël; F Chanussot; F Dodero; C de la Maisonneuve; R Lambert; J Brisse; A Chamlian
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

4.  Effects of mycophenolate mofetil vs cyclosporine administration on graft survival and function after islet allotransplantation in diabetic rats.

Authors:  Constantin Fotiadis; Paraskevi Xekouki; Apostolos E Papalois; Pantelis T Antonakis; Ioannis Sfiniadakis; Dimitrios Flogeras; Eleutheria Karampela; George Zografos
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

Review 5.  The metabolic effects of cyclosporin and tacrolimus.

Authors:  P Marchetti; R Navalesi
Journal:  J Endocrinol Invest       Date:  2000 Jul-Aug       Impact factor: 4.256

6.  Evaluation of the endothelin receptor antagonists ambrisentan, bosentan, macitentan, and sitaxsentan as hepatobiliary transporter inhibitors and substrates in sandwich-cultured human hepatocytes.

Authors:  Eve-Irene Lepist; Hunter Gillies; William Smith; Jia Hao; Cassandra Hubert; Robert L St Claire; Kenneth R Brouwer; Adrian S Ray
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

Review 7.  Cystic fibrosis related liver disease--another black box in hepatology.

Authors:  Katharina Staufer; Emina Halilbasic; Michael Trauner; Lili Kazemi-Shirazi
Journal:  Int J Mol Sci       Date:  2014-08-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.